VKH
DRNA

Virtu KCG Holdings’s Dicerna Pharmaceuticals, Inc. DRNA Stock Holding History

Virtu KCG Holdings’s Portfolio DRNA Stock Details DRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-28,099
Closed -$96K – 3674
2017
Q1 		$96K Buy
+28,099
New +$79.1K ﹤0.01% 2696

Other funds holding DRNA

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Virtu KCG Holdings's DRNA Position: Q2 2017 in Review

Virtu KCG Holdings sold out of Dicerna Pharmaceuticals, Inc. (DRNA) in Q2 2017, closing a stake of 28,099 shares — an estimated $96K sold.

Virtu KCG Holdings first reported a position in DRNA in Q1 2017 and held it in 1 quarter. The position peaked at $96K in Q1 2017. 36 funds tracked by Wall St. Rank hold DRNA as of Q2 2017.

  • Virtu KCG Holdings reported no remaining Dicerna Pharmaceuticals, Inc. position as of Q2 2017 after selling out during the quarter.
  • Virtu KCG Holdings sold 28,099 Dicerna Pharmaceuticals, Inc. shares in Q2 2017, an estimated $96K.
  • Virtu KCG Holdings first reported a position in Dicerna Pharmaceuticals, Inc. in Q1 2017 and held it in 1 quarter.
  • Virtu KCG Holdings's Dicerna Pharmaceuticals, Inc. position peaked at $96K in Q1 2017.
  • 36 funds tracked by Wall St. Rank held Dicerna Pharmaceuticals, Inc. as of Q2 2017.

Based on Virtu KCG Holdings's 13F filing for Q2 2017, filed 11 Aug 2017.